Dana-Farber Cancer Institute-Breast Oncology Center ( Site 0037) — Boston, Massachusetts

Dana-Farber Cancer Institute-Breast Oncology Center ( Site 0037) is a clinical research site located in Boston, Massachusetts, United States 02215.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Dana-Farber Cancer Institute-Breast Oncology Center ( Site 0037) has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Breast Neoplasms.

Sponsors: Merck Sharp & Dohme LLC.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Boston

Browse all research sites in Massachusetts · View every site in Boston

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Dana-Farber Cancer Institute-Breast Oncology Center ( Site 0037)?

Dana-Farber Cancer Institute-Breast Oncology Center ( Site 0037) has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Dana-Farber Cancer Institute-Breast Oncology Center ( Site 0037) conducted?

Dana-Farber Cancer Institute-Breast Oncology Center ( Site 0037) has 1 clinical trials on record, with 1 currently active. Their work covers Breast Neoplasms.

Is Dana-Farber Cancer Institute-Breast Oncology Center ( Site 0037) accredited by Crixeo Clinical Trials?

Dana-Farber Cancer Institute-Breast Oncology Center ( Site 0037) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Dana-Farber Cancer Institute-Breast Oncology Center ( Site 0037)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.